US Pharma MarketingAn early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.
BioNTech mRNA cancer immunotherapy misses first objective in key study
An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.
Source: BioPharma Dive